Samsara BioCapital

Summary

The main department of described Corporate Investor is located in the Palo Alto. The company was established in North America in United States.

The real fund results show that this Corporate Investor is 0 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Samsara BioCapital works on 1 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Samsara BioCapital, startups are often financed by Alta Partners, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Redmile Group, EcoR1 Capital, Cormorant Asset Management. In the next rounds fund is usually obtained by UBS Oncology Impact Fund, Redmile Group, EcoR1 Capital.

The overall number of key employees were 2.

We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, AlloVir For fund there is a match between the location of its establishment and the land of its numerous investments - United States.